RT Journal Article
SR Electronic
T1 Dasatinib for treatment of CAR T-cell therapy-related complications
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e005956
DO 10.1136/jitc-2022-005956
VO 10
IS 12
A1 Baur, Katharina
A1 Heim, Dominik
A1 Beerlage, Astrid
A1 Poerings, Anna S
A1 Kopp, Bastian
A1 Medinger, Michael
A1 Dirks, Jan C
A1 Passweg, Jakob R
A1 Holbro, Andreas
YR 2022
UL http://jitc.bmj.com/content/10/12/e005956.abstract
AB Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are severe, potentially life-threatening side effects of chimeric antigen receptor T-cell (CAR T) therapy caused by the release of cytokines by proliferating and activated CAR T-cells. Current mainstay treatment includes interleukin-1 and interleukin-6 (IL-6) blockade and steroids. The use of steroids is still controversial, since they may have the potential to irreversibly damage CAR T-cells and thus increase the risk of relapse. Therefore, additional treatment options need to be explored. We report the successful treatment of a patient with a grade 3 CRS and grade 4 ICANS refractory to IL-6 blockade and steroids with the tyrosine kinase inhibitor dasatinib. The use of dasatinib for treatment of CAR T-cell therapy-related severe complications warrants further studies.